Jan. 2026
The Fukuoka Association of Medical Sciences, Encouragement Award, The Fukuoka Association of Medical Sciences
Clinical impact of a subtype of urothelial carcinoma in non-muscle-invasive bladder cancer
Akinori Minato

Editorial Comment to "Clinical Outcomes and Clinicopathological Features of Primary Urethral Carcinoma: A Multicenter Retrospective Study in Japan".
Akinori Minato
International journal of urology : official journal of the Japanese Urological Association, Mar. 2026, Reviewed, No invitation
Lead

Eosinophilic vacuolated tumorと診断された腎腫瘍の1例
辻村 俊輝; 水嶋 唯; 杉田 佳弘; 松川 卓生; 渡邉 舟貴; 城嶋 和真; 木室 里依子; 東島 克佳; 永田 祐二郎; 湊 晶規; 富崎 一向; 柏木 英志
西日本泌尿器科, Feb. 2026, Reviewed, No invitation

鼠径部に生じたPleomorphic Hyalinizing Angiectatic Tumorの1例
永田 大輝; 杉田 佳弘; 水嶋 唯; 松川 卓生; 渡邉 舟貴; 城嶋 和真; 木室 里依子; 東島 克佳; 永田 祐二郎; 湊 晶規; 富崎 一向; 柏木 英志
西日本泌尿器科, Feb. 2026

後腹膜肉腫に対するエリブリン療法の治療成績
水嶋 唯; 湊 晶規; 高場 智久; 東島 克佳; 永田 祐二郎; 柏木 英志
泌尿器科紀要, Jan. 2026

組織異型を伴う尿路上皮癌特殊型に対するプラチナベース一次化学療法の検討
湊 晶規; 室岡 和樹; 大野 大地; 奥村 豊; 高場 智久; 東島 克佳; 永田 祐二郎; 富崎 一向; 原田 健一
泌尿器科紀要, Jan. 2026

当院における前立腺MRI-TRUS fusion biopsyの初期経験
山村 走平; 松本 正広; 坂東 太郎; 城嶋 和真; 高場 智久; 東島 克佳; 永田 祐二郎; 湊 晶規; 富崎 一向; 原田 健一
泌尿器科紀要, Jan. 2026

Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study.
Kosuke Ueda; Hiroki Kurata; Yoji Murakami; Akinori Minato; Masaki Shiota; Shotaro Nakanishi; Keijiro Kiyoshima; Toru Inoue; Hisaji Kumagae; Shinichiro Irie; Mitsuru Noguchi; Shuichi Tatarano; Hiroshi Matsuzaki; Yuji Tokuda; Atsuro Sawada; Tatsuro Abe; Yoshinori Oshiro; Shuji Harada; Tsukasa Igawa
International journal of clinical oncology, Jan. 2026, Reviewed, No invitation
Lead

Multicenter Retrospective Analysis of Acute Scrotum in the Kyushu-Okinawa Region: Diagnostic Practices, Management Patterns, and Predictors of Testicular Salvage.
Shohei Tobu; Yuka Kakinoki; Tatsuo Konomoto; Takeshi Shono; Chie Onizuka; Masahiro Todaka; Akinori Minato; Junki Harada; Shotaro Nakanishi; Nobuhiro Haga; Yuichi Nakashima; Kouji Nagata; Yo Satoji; Keisuke Yano; Atsumi Uemura; Seiji Tanaka; Mitsuru Noguchi
International journal of urology : official journal of the Japanese Urological Association, Jan. 2026, Reviewed, No invitation
Lead

Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
Akinori Minato; Kazumasa Jojima; Shuki Watanabe; Yoshihiro Sugita; Yui Mizushima; Takuo Matsukawa; Rieko Kimuro; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi
Cancer diagnosis & prognosis, 2026

転移性尿路上皮癌の一次化学療法におけるゲムシタビン+カルボプラチン療法の有効性
東島 克佳; 湊 晶規; 杉田 佳弘; 水嶋 唯; 渡邉 舟貴; 城嶋 和真; 木室 里依子; 永田 祐二郎; 富崎 一向; 柏木 英志
西日本泌尿器科, Dec. 2025, Reviewed, No invitation

Editorial Comment to "Does Accessory Pudendal Artery Preservation Increase the Risk of Positive Surgical Margins in Robot-Assisted Radical Prostatectomy?".
Akinori Minato
International journal of urology : official journal of the Japanese Urological Association, Dec. 2025, Reviewed, No invitation
Lead

腎盂尿管癌に対する腎尿管全摘除術後の予後の検討
木室 里依子; 湊 晶規; 富崎 一向; 柏木 英志; 藤本 直浩
日本泌尿器科学会雑誌, Oct. 2025, Reviewed, No invitation

Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
Akinori Minato; Tomohisa Takaba; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi
International journal of urology : official journal of the Japanese Urological Association, Sep. 2025, Reviewed, No invitation
Lead

若年者の陰茎癌に対して陰茎部分切除術を施行し性機能を温存できた1例
高場 智久; 松川 卓生; 城嶋 和真; 東島 克佳; 永田 祐二郎; 湊 晶規; 富崎 一向; 柏木 英志
日本性機能学会雑誌, Aug. 2025, Reviewed, No invitation

精巣傍部軟部肉腫の治療と長期予後に関する後方視的検討 単一施設18例の解析
湊 晶規; 杉田 佳弘; 水嶋 唯; 渡邉 舟貴; 木室 里依子; 東島 克佳; 永田 祐二郎; 富崎 一向; 柏木 英志
西日本泌尿器科, Aug. 2025, Reviewed, No invitation

Adjuvant Nivolumab Therapy for Upper Tract Urothelial Carcinoma: A Single-Institution Study.
Akinori Minato; Katsuyoshi Higashijima; Yui Mizushima; Yoshihiro Sugita; Kazumasa Jojima; Rieko Kimuro; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi; Naohiro Fujimoto
Cureus, Aug. 2025, Reviewed, No invitation
Lead

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Akinori Minato; Tomohisa Takaba; Yoshihiro Sugita; Yuya Kaneko; Ryota Hongyo; Toshinobu Tanaka; Taro Bando; Takaomi Sugi; Yui Mizushima; Takuo Matsukawa; Kazumasa Jojima; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi
Japanese journal of clinical oncology, Jul. 2025, Reviewed, No invitation
Lead

当院における急性陰嚢症に対して精巣摘除した5例の検討
渡邉 舟貴; 松本 博臣; 湊 晶規; 柏木 英志
日本小児泌尿器科学会雑誌, Jul. 2025, Reviewed, No invitation

75歳以上の高齢男性におけるロボット支援前立腺全摘除術
杉 貴臣; 松川 卓生; 坂東 太郎; 高場 智久; 城嶋 和真; 東島 克佳; 永田 祐二郎; 湊 晶規; 富崎 一向; 柏木 英志
日本老年泌尿器科学会誌, Jul. 2025, Reviewed, No invitation

九州沖縄地区における急性陰嚢症の診療実態調査報告
東武 昇平; 柿木 優佳; 此元 竜雄; 鬼塚 千衣; 秦 聡孝; 猪口 淳一; 今村 亮一; 宮崎 健; 永田 公二; 里地 葉; 家入 里志; 中島 雄一; 田中 征治; 生野 猛; 湊 晶規; 植村 篤実; 野口 満
日本小児泌尿器科学会雑誌, Jul. 2025

膀胱尿管逆流症に対するカラードプラ法超音波検査による尿管口jet角の検討
渡邉 舟貴; 大野 大地; 松本 博臣; 小野 友輔; 湊 晶規; 柏木 英志
日本小児泌尿器科学会雑誌, Jul. 2025, Reviewed, No invitation

進行性尿路上皮癌に対するエンホルツマブベドチン単剤療法のrelative dose intensityの検討
杉田 佳弘; 湊 晶規; 高場 智久; 金子 雄哉; 本行 遼太; 坂東 太郎; 田中 敏信; 杉 貴臣; 水嶋 唯; 松川 卓生; 城嶋 和真; 東島 克佳; 永田 祐二郎; 富崎 一向; 柏木 英志
西日本泌尿器科, Jun. 2025, Reviewed, No invitation

未治療進行性尿路上皮癌に対するエンホルツマブ・ベドチンとペムブロリズマブ併用療法の初期経験
金子 雄哉; 杉田 佳弘; 湊 晶規; 本行 遼太; 坂東 太郎; 田中 敏信; 杉 貴臣; 水嶋 唯; 松川 卓生; 高場 智久; 城嶋 和真; 東島 克佳; 永田 祐二郎; 富崎 一向; 柏木 英志
西日本泌尿器科, Jun. 2025, Reviewed, No invitation

Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer.
Akinori Minato; Moena Yoshii; Shuki Watanabe; Ryosuke Moriya; Eiji Kashiwagi; Naohiro Fujimoto
Japanese journal of clinical oncology, Apr. 2025, Reviewed, No invitation
Lead

吸引分娩後に難治性の膀胱腟瘻をきたした1例
関亦 真生; 田尻 亮祐; 齋藤 佑真; 飯尾 一陽; 近藤 恵美; 吉村 和晃; 湊 晶規; 新村 友季子; 吉野 潔
日本女性骨盤底医学会誌, Mar. 2025, Reviewed, No invitation

膀胱神経内分泌癌に対する臨床的検討
呉竹 景介; 湊 晶規; 原田 修治; 藤本 直浩
日本泌尿器科学会雑誌, Jan. 2025, Reviewed, No invitation

Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Kazumasa Jojima; Akinori Minato; Hirotsugu Noguchi; Yojiro Tsuda; Naohiro Fujimoto
Cancer diagnosis & prognosis, 2025, Reviewed, No invitation
Corresponding

Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma on Dialysis: A Case Report.
Yuto Tsubonuma; Yujiro Nagata; Katsuyoshi Higashijima; Akinori Minato; Ikko Tomisaki; Naohiro Fujimoto
Cureus, Jan. 2025, Reviewed, No invitation
Corresponding

Prostate-specific Antigen Decline During Primary Androgen-deprivation Therapy for Predicting Response and Survival in Metastatic Castration-resistant Prostate Cancer Patients Receiving Enzalutamide.
Yujiro Nagata; Takaomi Sugi; Sohei Yamamura; Yoshihiro Sugita; Yui Mizushima; Takuo Matsukawa; Tomohisa Takaba; Kazumasa Jojima; Katsuyoshi Higashijima; Masahiro Matsumoto; Akinori Minato; Ikko Tomisaki; Eiji Kashiwagi; Naohiro Fujimoto
In vivo (Athens, Greece), 2025, Reviewed, No invitation

Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.
Akinori Minato; Yui Mizushima; Yoshihiro Sugita; Tomohisa Takaba; Takuo Matsukawa; Kazumasa Jojima; Rieko Kimuro; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Eiji Kashiwagi; Naohiro Fujimoto
In vivo (Athens, Greece), 2025, Reviewed, No invitation
Lead

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.
Eiji Kashiwagi; Miho Ushijima; Shohei Ueda; Yoshihiro Sugita; Yui Mizushima; Takuo Matsukawa; Rieko Kimuro; Kazumasa Jojima; Katsuyoshi Higashijima; Yujiro Nagata; Akinori Minato; Ikko Tomisaki; Masatoshi Eto
Journal of kidney cancer and VHL, 2025, Reviewed, No invitation
Corresponding

[CLINICAL OUTCOMES OF NEUROENDOCRINE CARCINOMA OF THE URINARY BLADDER].
Keisuke Kuretake; Akinori Minato; Shuji Harada; Naohiro Fujimoto
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2025, Reviewed, No invitation

Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes.
Ikko Tomisaki; Mirii Harada; Shigeru Sakano; Michikazu Terado; Ryoichi Hamasuna; Shuji Harada; Hiroomi Matsumoto; Soichiro Akasaka; Yujiro Nagata; Akinori Minato; Ken-Ichi Harada; Naohiro Fujimoto
Oncology letters, Dec. 2024

Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Akinori Minato; Nobuki Furubayashi; Toshihisa Tomoda; Hiroyuki Masaoka; Yoohyun Song; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Kentaro Kuroiwa; Narihito Seki; Ikko Tomisaki; Kenichi Harada; Motonobu Nakamura; Naohiro Fujimoto
Clinical genitourinary cancer, Oct. 2024

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Yujiro Nagata; Akinori Minato; Hisami Aono; Rieko Kimuro; Katsuyoshi Higashijima; Ikko Tomisaki; Kenichi Harada; Hiroshi Miyamoto; Naohiro Fujimoto
International journal of molecular sciences, Sep. 2024

Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Nobuki Furubayashi; Akinori Minato; Toshihisa Tomoda; Hiroyuki Masaoka; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Yusuke Haraguchi; Toshiki Koga; Yoohyun Song; Kenichi Harada; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Anticancer research, Aug. 2024

Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy.
Akinori Minato; Nobuki Furubayashi; Toshihisa Tomoda; Hiroyuki Masaoka; Yoohyun Song; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Kentaro Kuroiwa; Narihito Seki; Ikko Tomisaki; Motonobu Nakamura; Kenichi Harada; Naohiro Fujimoto
Anticancer research, Aug. 2024

Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Akinori Minato; Nobuki Furubayashi; Toshihisa Tomoda; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Kentaro Kuroiwa; Ikko Tomisaki; Kenichi Harada; Motonobu Nakamura; Naohiro Fujimoto
Translational andrology and urology, Jul. 2024

Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Nobuki Furubayashi; Akinori Minato; Toshihisa Tomoda; Hiroyuki Masaoka; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Yusuke Haraguchi; Toshiki Koga; Yoohyun Song; Kenichi Harada; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Anticancer research, Jul. 2024

Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
Nobuki Furubayashi; Akinori Minato; Toshihisa Tomoda; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Yusuke Haraguchi; Toshiki Koga; Kenichi Harada; Kentaro Kuroiwa; Naohiro Fujimoto; Motonobu Nakamura
Anticancer research, Apr. 2024

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Akinori Minato; Nobuki Furubayashi; Yujiro Nagata; Toshihisa Tomoda; Hiroyuki Masaoka; Yoohyun Song; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Kentaro Kuroiwa; Narihito Seki; Ikko Tomisaki; Kenichi Harada; Motonobu Nakamura; Naohiro Fujimoto
Current oncology (Toronto, Ont.), Feb. 2024

Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
Akinori Minato; Kazuki Murooka; Yutaka Okumura; Tomohisa Takaba; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto
In vivo (Athens, Greece), 2024

Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
Yuto Tsubonuma; Keita Funakoshi; Tomohisa Takaba; Kazumasa Jyojima; Akinori Minato; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto
Journal of UOEH, 2024

Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Akinori Minato; Daichi Ohno; Kazuki Murooka; Yutaka Okumura; Tomohisa Takaba; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto
In vivo (Athens, Greece), 2024

The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.
Naohiro Fujimoto; Yujiro Nagata; Masaki Shiota; Akinori Minato; Ikko Tomisaki; Kenichi Harada; Masatoshi Eto; Hiroshi Miyamoto
In vivo (Athens, Greece), 2024

Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Nobuki Furubayashi; Akinori Minato; Toshihisa Tomoda; Yoshifumi Hori; Keijiro Kiyoshima; Takahito Negishi; Yusuke Haraguchi; Toshiki Koga; Kentaro Kuroiwa; Naohiro Fujimoto; Motonobu Nakamura
Anticancer research, Dec. 2023

Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Hiroyuki Masaoka; Mirii Harada; Shingo Tamura; Hiroki Kobayashi; Kaede Morihara; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Anticancer research, Oct. 2023

Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Ikko Tomisaki; Mirii Harada; Shigeru Sakano; Michikazu Terado; Ryoichi Hamasuna; Shuji Harada; Hiroomi Matsumoto; Soichiro Akasaka; Yujiro Nagata; Akinori Minato; Ken-Ichi Harada; Naohiro Fujimoto
International journal of urology : official journal of the Japanese Urological Association, Sep. 2023

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Naohiro Fujimoto; Yuto Tsubonuma; Yujiro Nagata; Akinori Minato; Ikko Tomisaki; Kenichi Harada; Hiroshi Miyamoto
Anticancer research, Sep. 2023

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Akinori Minato; Rieko Kimuro; Daichi Ohno; Kentarou Tanigawa; Keisuke Kuretake; Takuo Matsukawa; Tomohisa Takaba; Kazumasa Jojima; Mirii Harada; Katsuyoshi Higashijima; Yujiro Nagata; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto; Hiroshi Miyamoto
Anticancer research, Sep. 2023

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Ikko Tomisaki; Mirii Harada; Shigeru Sakano; Michikazu Terado; Ryoichi Hamasuna; Shuji Harada; Hiroomi Matsumoto; Soichiro Akasaka; Yujiro Nagata; Akinori Minato; Ken-Ichi Harada; Naohiro Fujimoto
Anticancer research, Jan. 2023

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Akinori Minato; Ikko Tomisaki; Rieko Kimuro; Katsuyoshi Higashijima; Mirii Harada; Kazumasa Jojima; Takuro Sakamoto; Tomohisa Takaba; Daichi Ohno; Keisuke Kuretake; Kentarou Tanigawa; Takuo Matsukawa; Kenichi Harada; Naohiro Fujimoto
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023

Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis.
Akinori Minato; Yuzan Kudo; Hirotsugu Noguchi; Shiro Kohi; Yoshitaka Hasegawa; Norihiro Sato; Keiji Hirata; Naohiro Fujimoto
Cancer genomics & proteomics, 2023

Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Akinori Minato; Nobuki Furubayashi; Mirii Harada; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Shingo Tamura; Kentaro Kuroiwa; Narihito Seki; Ikko Tomisaki; Kenichi Harada; Motonobu Nakamura; Naohiro Fujimoto
Clinical genitourinary cancer, Oct. 2022

Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Naohiro Fujimoto; Akinori Minato; Tsukasa Igawa; Tasuku Hiroshige; Wataru Obara; Atsushi Fukuda; Yujiro Nagata; Yui Mizushima; Ikko Tomisaki; Kenichi Harada
Anticancer research, Jun. 2022

Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Ikko Tomisaki; Mirii Harada; Akinori Minato; Yujiro Nagata; Rieko Kimuro; Katsuyoshi Higashijima; Kenichi Harada; Naohiro Fujimoto
Anticancer research, Mar. 2022

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Akinori Minato; Hirotsugu Noguchi; Rieko Kimuro; Harada Mirii; Nagata Yujiro; Yoshitaka Hasegawa; Ikko Tomisaki; Kenichi Harada; Naohiro Fujimoto
Anticancer research, Jan. 2022

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Mirii Harada; Shingo Tamura; Akihiro Miura; Hiroki Komori; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Cancer management and research, 2022

[Clinical Statistics From 2017 to 2019 in the Department of Urology, Hospital of the University of the Occupational and Environmental Health, Japan].
Kazuki Murooka; Ryousuke Moriya; Gosuke Yamasaki; Keiko Iwakuma; Katsuyoshi Higashijima; Rei Onishi; Akinori Minato; Masahiro Matsumoto; Ikko Tomisaki; Naohiro Fujimoto
Journal of UOEH, 2022

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Mirii Harada; Shingo Tamura; Hiroki Kobayashi; Yamato Wada; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
OncoTargets and therapy, 2022

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Naohiro Fujimoto; Kenichi Harada; Masaki Shiota; Ikko Tomisaki; Akinori Minato; Yujiro Nagata; Rieko Kimuro; Mirii Harada; Masato Fujisawa
Anticancer research, Oct. 2021

Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Mirii Harada; Ikko Tomisaki; Akinori Minato; Rei Onishi; Michikazu Terado; Hisato Inatomi; Naohiro Fujimoto
International journal of urology : official journal of the Japanese Urological Association, Sep. 2021

Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.
Akinori Minato; Hirotsugu Noguchi; Rei Ohnishi; Ikko Tomisaki; Toshiyuki Nakayama; Naohiro Fujimoto
In vivo (Athens, Greece), 2021

Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer.
Naohiro Fujimoto; Masaki Shiota; Takuo Matsukawa; Akinori Minato; Ikko Tomisaki; Rei Ohnishi; Masatoshi Eto
In vivo (Athens, Greece), 2021

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
Kenichi Harada; Masaki Shiota; Akinori Minato; Masahiro Matsumoto; Ikko Tomisaki; Masato Fujisawa; Naohiro Fujimoto
OncoTargets and therapy, 2021

Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Ikko Tomisaki; Mirii Harada; Kei Tokutsu; Akinori Minato; Yujiro Nagata; Rieko Kimuro; Masahiro Matsumoto; Naohiro Fujimoto
In vivo (Athens, Greece), 2021

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Shingo Tamura; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Cancer management and research, 2021

Evaluation of the Extent of Variant Histology in Urothelial Carcinoma as a Predictive Marker of Clinical Outcomes After Radical Cystectomy.
Akinori Minato; Hirotsugu Noguchi; Ryosuke Moriya; Katsuyoshi Higashijima; Gosuke Yamasaki; Rieko Kimuro; Yoshitaka Hasegawa; Ikko Tomisaki; Naohiro Fujimoto
Cancer diagnosis & prognosis, 2021

Premature Mortality Due to Malignancies of the Kidney and Bladder in Japan, 1980-2010.
Truong-Minh Pham; Tatsuhiko Kubo; Yoshihisa Fujino; Naohiro Fujimoto; Ikko Tomisaki; Akinori Minato; Shinya Matsuda
Journal of epidemiology, Dec. 2019

Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer.
Naohiro Fujimoto; Masaki Shiota; Ikko Tomisaki; Akinori Minato; Katsuya Yahara
Urologia internationalis, 2019

Oncological Outcome After Radical Prostatectomy without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Ikko Tomisaki; Hirofumi Ikuta; Katsuyoshi Higashijima; Rei Onishi; Akinori Minato; Naohiro Fujimoto
Cancer investigation, 2019

Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Ikko Tomisaki; Tatsuhiko Kubo; Akinori Minato; Naohiro Fujimoto
Cancer investigation, Feb. 2018

[INVASIVE BLADDER CANCER PRODUCING GRANULOCYTE-COLONY STIMULATING FACTOR: A CASE REPORT].
Akinori Minato; Naohiro Fujimoto; Ikko Tomisaki; Seigen Yamasaki; Michitaka Nakashima; Kosuke Makihara
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2018

Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Akinori Minato; Hirotsugu Noguchi; Ikko Tomisaki; Atsushi Fukuda; Tatsuhiko Kubo; Toshiyuki Nakayama; Naohiro Fujimoto
Cancer control : journal of the Moffitt Cancer Center, 2018

Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
Akinori Minato; Naohiro Fujimoto; Tatsuhiko Kubo
Clinical genitourinary cancer, Dec. 2017

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.
Naohiro Fujimoto; Masaki Shiota; Ikko Tomisaki; Akinori Minato
Clinical genitourinary cancer, Jun. 2017

Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.
Akinori Minato; Naohiro Fujimoto; Tatsuhiko Kubo; Shuji Harada; Soichiro Akasaka; Tetsuro Matsumoto
Medical oncology (Northwood, London, England), Dec. 2012

副腎腫瘍に対する鏡視下副腎摘除術の検討　到達法別の治療成績の比較検討
大西 怜, 東島 克佳, 岩隈 景子, 守屋 良介, 湊 晶規, 富崎 一向, 藤本 直浩
Japanese Journal of Endourology, Apr. 2020, Reviewed, No invitation

ソフト凝固を用いた無阻血無縫合腹腔鏡下腎部分切除術における術後腎機能の検討
宮崎 一向, 大西 怜, 湊 晶規, 濱砂 良一, 藤本 直浩
Japanese Journal of Endourology, Apr. 2019, Reviewed, No invitation

非典型的な主訴で来院した梅毒の2例
呉竹景介、舟越恵太、野間悠太朗、谷川堅太郎、大野大地、松川卓生、高場智久、城嶋和真、原田みりい、木室里依子、東島克佳、永田祐二郎、湊 晶規、富崎一向、原田健一、藤本直浩、岡田悦子
日本性感染症学会誌, Sep. 2023, Reviewed, No invitation

非典型的な主訴で来院した梅毒の2例
呉竹 景介, 舟越 恵太, 野間 悠太朗, 谷川 堅太郎, 大野 大地, 松川 卓生, 高場 智久, 城嶋 和真, 原田 みりい, 木室 里依子, 東島 克佳, 永田 祐二郎, 湊 晶規, 富崎 一向, 原田 健一, 藤本 直浩, 岡田 悦子
日本性感染症学会誌, Mar. 2024, Reviewed, No invitation

膀胱神経内分泌癌に対する臨床的検討
呉竹 景介, 湊 晶規, 原田 修治, 藤本 直浩
日本泌尿器科学会雑誌, Jan. 2025, Reviewed, No invitation

局所進行膀胱癌に対する膀胱全摘除術後補助化学療法の有効性
湊 晶規, 富崎 一向, 木室 里依子, 東島 克佳, 原田 みりい, 城嶋 和真, 坂本 卓郎, 高場 智久, 大野 大地, 呉竹 景介, 谷川 堅太郎, 松川 卓生, 原田 健一, 藤本 直浩
日本泌尿器科学会雑誌, Oct. 2023, Reviewed, No invitation
Lead

顆粒球コロニー刺激因子(G-CSF)産生浸潤性膀胱癌の1例　本邦報告例のまとめ
湊 晶規, 藤本 直浩, 富崎 一向, 山崎 清玄, 中島 信能, 槇原 康亮
日本泌尿器科学会雑誌, Jul. 2018, Reviewed, No invitation
Lead

前立腺全摘除術を施行したStromal tumor of uncertain malignant potential(STUMP)の1例
湊 晶規, 上領 頼之, 中島 信能, 槇原 康亮, 藤本 直浩
泌尿器外科, Oct. 2017, Reviewed, No invitation
Lead

去勢抵抗性前立腺癌に対して、間欠的にドセタキセルによる化学療法を施行した症例の治療成績
湊 晶規, 富崎 一向, 久保 達彦, 藤本 直浩
泌尿器外科, Aug. 2016, Not reviewed, Invited
Lead

産業医科大学病院泌尿器科における2017年から2019年の臨床統計
室岡 和樹, 守屋 良介, 山崎 豪介, 岩隈 景子, 東島 克佳, 大西 怜, 湊 晶規, 松本 正広, 富崎 一向, 藤本 直浩
産業医科大学雑誌, Jun. 2022, Reviewed, No invitation

ミトタン+EDP療法を施行した進行副腎皮質癌
湊 晶規, 野口 紘嗣, 富崎 一向, 生田 弘文, 永田 祐二郎, 藤本 直浩
臨床泌尿器科, Sep. 2018, Reviewed, No invitation
Lead

eribulinが著効した後腹膜脱分化型脂肪肉腫の一例
水嶋 唯, 富崎 一向, 寺戸 三千和, 稲富 久人, 湊 晶規, 原田 健一, 藤本 直浩, 原田 佳和, 島尻 正平, 中山 敏幸
西日本泌尿器科, Jun. 2023, Reviewed, No invitation

希少がん;Next 10 Years　後腹膜肉腫に対する薬物療法
湊 晶規, 藤本 直浩
西日本泌尿器科, Apr. 2023, Reviewed, No invitation
Lead

尿道原発悪性リンパ腫の1例
杉田 佳弘, 原田 みりい, 山村 走平, 安田 幸平, 木室 里依子, 東島 克佳, 松本 正広, 湊 晶規, 富崎 一向, 島尻 正平, 藤本 直浩
西日本泌尿器科, Jun. 2022, Reviewed, No invitation

前立腺粘液腺癌の1例
安田 幸平, 湊 晶規, 木室 里依子, 岩隈 景子, 富崎 一向, 藤本 直浩
西日本泌尿器科, Apr. 2022, Reviewed, No invitation

Paclitaxelおよび放射線療法が著効した膀胱原発血管肉腫の1例
大野大地、富﨑一向、守屋良介、東島克佳、大西怜、湊晶規、寺戸三千和、稲富久人、松山篤二、島尻正平、藤本直浩
西日本泌尿器科, 2021, Reviewed, No invitation

SunitinibとVDC-IE療法が有効であった腎Ewing肉腫の1例
奥村 豊, 守屋 良介, 大西 怜, 湊 晶規, 松本 正広, 富崎 一向, 藤本 直浩, 津田 陽二郎
西日本泌尿器科, Dec. 2021, Reviewed, Null

ロボット支援腹腔鏡下膀胱全摘除術の初期症例における周術期成績の検討
富崎 一向, 大西 怜, 山村 走平, 木室 里依子, 生田 弘文, 湊 晶規, 藤本 直浩, 濱砂 良一
西日本泌尿器科, Feb. 2021, Reviewed, Null

前立腺癌に対するビカルタミド単剤投与中に認めた男性子宮内膜症の1例
岩隈 景子, 湊 晶規, 富崎 一向, 藤本 直浩, 寺戸 三千和, 稲富 久人, 秋葉 純
西日本泌尿器科, Dec. 2020, Reviewed, No invitation

エリスロポエチン産生乳頭状腎細胞癌の1例
木室 里依子, 湊 晶規, 安田 幸平, 渡邉 舟貴, 中村 仁美, 寺戸 三千和, 稲富 久人, 渡邉 三恵, 秋葉 純, 藤本 直浩
西日本泌尿器科, Dec. 2020, Reviewed, No invitation

集学的治療を行った扁平上皮への分化を伴う膀胱尿路上皮癌
湊 晶規, 藤本 直浩, 岩渕 直人, 原田 修治
西日本泌尿器科, Aug. 2020, Reviewed, No invitation
Lead

女性尿道憩室に発生した明細胞腺癌の1例
湊 晶規, 藤本 直浩, 上領 頼之, 中島 信能, 槇原 康亮
西日本泌尿器科, Feb. 2018, Reviewed, No invitation
Lead

膀胱尿路上皮癌特殊型の臨床的意義
湊 晶規, 藤本 直浩, 野口 紘嗣
西日本泌尿器科, Dec. 2018, Reviewed, No invitation
Lead

術前生検によって確定診断が困難であった陰茎乳房外浸潤性Paget病の1例
生田 弘文, 西井 久枝, 永田 祐二郎, 湊 晶規, 松本 正広, 富崎 一向, 濱砂 良一, 藤本 直浩, 木下 俊輔, 大栗 隆行, 興梠 征典, 松山 篤二
西日本泌尿器科, Oct. 2016, Reviewed, No invitation

Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Nakamura Motonobu, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Aug. 2024, Reviewed, No invitation
Lead

Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Masaoka Hiroyuki, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Song Yoohyun, Harada Kenichi, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu,
Anticancer research, Aug. 2024, Reviewed, No invitation

Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Masaoka Hiroyuki, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Song Yoohyun, Harada Kenichi, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu,
Anticancer research, Jul. 2024, Reviewed, No invitation

Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Harada Kenichi, Kuroiwa Kentaro, Fujimoto Naohiro, Nakamura Motonobu,
Anticancer research, Apr. 2024, Reviewed, No invitation

Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Minato Akinori, Kimuro Rieko, Ohno Daichi, Tanigawa Kentarou, Kuretake Keisuke, Matsukawa Takuo, Takaba Tomohisa, Jojima Kazumasa, Harada Mirii, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Reviewed, No invitation
Lead

Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Fujimoto Naohiro, Tsubonuma Yuto, Nagata Yujiro, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Miyamoto Hiroshi
Anticancer research, Sep. 2023, Reviewed, No invitation

Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Furubayashi Nobuki, Minato Akinori, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Haraguchi Yusuke, Koga Toshiki, Kuroiwa Kentaro, Fujimoto Naohiro, Nakamura Motonobu
Anticancer research, Dec. 2023, Reviewed, No invitation

Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Furubayashi Nobuki, Minato Akinori, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Masaoka Hiroyuki, Harada Mirii, Tamura Shingo, Kobayashi Hiroki, Morihara Kaede, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu
Anticancer research, Oct. 2023, Reviewed, No invitation

Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
Anticancer research, Jan. 2023, Reviewed, No invitation

Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
Fujimoto Naohiro, Minato Akinori, Igawa Tsukasa, Hiroshige Tasuku, Obara Wataru, Fukuda Atsushi, Nagata Yujiro, Mizushima Yui, Tomisaki Ikko, Harada Kenichi
Anticancer research, Jun. 2022, Reviewed, No invitation

Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki Ikko, Harada Mirii, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Higashijima Katsuyoshi, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Mar. 2022, Reviewed, No invitation

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Minato Akinori, Noguchi Hirotsugu, Kimuro Rieko, Mirii Harada, Yujiro Nagata, Hasegawa Yoshitaka, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Jan. 2022, Reviewed, No invitation
Lead

Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Fujimoto Naohiro, Harada Kenichi, Shiota Masaki, Tomisaki Ikko, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Harada Mirii, Fujisawa Masato
Anticancer research, Oct. 2021, Reviewed, No invitation

Evaluation of the extent of variant histology in urothelial carcinoma as a predictive_x000D_ marker of clinical outcomes after radical cystectomy.
Minato A, Noguchi H, Moriya R, Higashijima K, Yamasaki G, Kimuro R, Hasegawa Y, Tomisaki I, Fujimoto N.
Cancer Diagnosis Prognosis, Jul. 2021, Reviewed, No invitation
Lead

Oncological Outcome After Radical Prostatectomy Without Pelvic Lymph Node Dissection for Localized Prostate Cancer: Follow-up Results in a Single Institution.
Ikko Tomisaki , Hirofumi Ikuta , Katsuyoshi Higashijima , Rei Onishi , Akinori Minato , Naohiro Fujimoto
Cancer Investigation, Oct. 2019, Reviewed, No invitation

Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato Akinori, Noguchi Hirotsugu, Tomisaki Ikko, Fukuda Atsushi, Kubo Tatsuhiko, Nakayama Toshiyuki, Fujimoto Naohiro
Cancer control : journal of the Moffitt Cancer Center, Sep. 2018, Reviewed, No invitation
Lead

Clinical Outcomes of Micropapillary Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Jojima Kazumasa, Minato Akinori, Noguchi Hirotsugu, Tsuda Yojiro, Fujimoto Naohiro
Cancer diagnosis & prognosis, 2025, Reviewed, No invitation

Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis.
Minato Akinori, Kudo Yuzan, Noguchi Hirotsugu, Kohi Shiro, Hasegawa Yoshitaka, Sato Norihiro, Hirata Keiji, Fujimoto Naohiro
Cancer genomics & proteomics, Mar. 2023, Reviewed, No invitation
Lead

Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
Tomisaki Ikko, Kubo Tatsuhiko, Minato Akinori, Fujimoto Naohiro
Cancer investigation, Feb. 2018, Reviewed, No invitation

Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Furubayashi Nobuki, Minato Akinori, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Harada Mirii, Tamura Shingo, Miura Akihiro, Komori Hiroki, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu
Cancer management and research, Sep. 2022, Reviewed, No invitation

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Furubayashi Nobuki, Minato Akinori, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Tamura Shingo, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu
Cancer management and research, Oct. 2021, Reviewed, No invitation

Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Clinical genitourinary cancer, Oct. 2024, Reviewed, No invitation
Lead

Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Harada Mirii, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Tamura Shingo, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Clinical genitourinary cancer, Oct. 2022, Reviewed, Null
Lead

Squamous Differentiation Predicts Poor Response to Cisplatin-Based Chemotherapy and Unfavorable Prognosis in Urothelial Carcinoma of the Urinary Bladder.
Minato Akinori, Fujimoto Naohiro, Kubo Tatsuhiko
Clinical genitourinary cancer, Jul. 2017, Reviewed, No invitation
Lead, Corresponding

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer.
Fujimoto Naohiro, Shiota Masaki, Tomisaki Ikko, Minato Akinori
Clinical genitourinary cancer, Jan. 2017, Reviewed, No invitation
Last

Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma on Dialysis: A Case Report.
Tsubonuma Yuto, Nagata Yujiro, Higashijima Katsuyoshi, Minato Akinori, Tomisaki Ikko, Fujimoto Naohiro
Cureus, Jan. 2025, Reviewed, No invitation

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato Akinori, Furubayashi Nobuki, Nagata Yujiro, Tomoda Toshihisa, Masaoka Hiroyuki, Song Yoohyun, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Seki Narihito, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Current oncology (Toronto, Ont.), Feb. 2024, Reviewed, No invitation
Lead

Three-month prostate-specific antigen level after androgen deprivation therapy predicts survival in patients with metastatic castration-sensitive prostate cancer.
Fujimoto N, Shiota M, Matsukawa T, Minato A, Tomisaki I, Ohnishi R, Eto M
In Vivo, Mar. 2021, Reviewed, No invitation

The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.
Fujimoto Naohiro, Nagata Yujiro, Shiota Masaki, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Eto Masatoshi, Miyamoto Hiroshi
In vivo (Athens, Greece), 2024, Reviewed, No invitation

Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Minato Akinori, Ohno Daichi, Murooka Kazuki, Okumura Yutaka, Takaba Tomohisa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
In vivo (Athens, Greece), 2024, Reviewed, No invitation
Lead

Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology.
Minato Akinori, Murooka Kazuki, Okumura Yutaka, Takaba Tomohisa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
In vivo (Athens, Greece), 2024, Reviewed, No invitation
Lead

Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.
Tomisaki Ikko, Harada Mirii, Tokutsu Kei, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Matsumoto Masahiro, Fujimoto Naohiro
In vivo (Athens, Greece), Nov. 2021, Reviewed, No invitation
Corresponding

Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.
Minato Akinori, Noguchi Hirotsugu, Ohnishi Rei, Tomisaki Ikko, Nakayama Toshiyuki, Fujimoto Naohiro
In vivo (Athens, Greece), Apr. 2021, Reviewed, No invitation
Lead

Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Nagata Yujiro, Minato Akinori, Aono Hisami, Kimuro Rieko, Higashijima Katsuyoshi, Tomisaki Ikko, Harada Kenichi, Miyamoto Hiroshi, Fujimoto Naohiro
International journal of molecular sciences, Sep. 2024, Reviewed, No invitation

Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
International journal of urology : official journal of the Japanese Urological Association, Sep. 2023, Reviewed, No invitation

Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.
Harada Ken-Ichi, Miyake Hideaki, Furukawa Junya, Fujimoto Naohiro, Fujisawa Masato
International journal of urology : official journal of the Japanese Urological Association, Aug. 2022, Reviewed, No invitation

Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Harada Mirii, Tomisaki Ikko, Minato Akinori, Onishi Rei, Terado Michikazu, Inatomi Hisato, Fujimoto Naohiro
International journal of urology : official journal of the Japanese Urological Association, Jul. 2021, Reviewed, No invitation
Corresponding

Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma.
Minato Akinori, Takaba Tomohisa, Sugita Yoshihiro, Kaneko Yuya, Hongyo Ryota, Tanaka Toshinobu, Bando Taro, Sugi Takaomi, Mizushima Yui, Matsukawa Takuo, Jojima Kazumasa, Higashijima Katsuyoshi, Nagata Yujiro, Tomisaki Ikko, Kashiwagi Eiji
Japanese journal of clinical oncology, Mar. 2025, Reviewed, No invitation
Lead

Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer.
Minato Akinori, Yoshii Moena, Watanabe Shuki, Moriya Ryosuke, Kashiwagi Eiji, Fujimoto Naohiro
Japanese journal of clinical oncology, Apr. 2025, Reviewed, No invitation
Lead

Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
Tsubonuma Yuto, Funakoshi Keita, Takaba Tomohisa, Jyojima Kazumasa, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Journal of UOEH, 2024, Reviewed, No invitation

Premature mortality due to malignancies of the kidney and bladder in Japan, 1980-2010.
Pham Truong-Minh, Kubo Tatsuhiko, Fujino Yoshihisa, Fujimoto Naohiro, Tomisaki Ikko, Minato Akinori, Matsuda Shinya
Journal of epidemiology, Nov. 2018, Reviewed, No invitation

[IMPACT OF ADJUVANT CHEMOTHERAPY AFTER RADICAL CYSTECTOMY FOR PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER].
Minato Akinori, Tomisaki Ikko, Kimuro Rieko, Higashijima Katsuyoshi, Harada Mirii, Jojima Kazumasa, Sakamoto Takuro, Takaba Tomohisa, Ohno Daichi, Kuretake Keisuke, Tanigawa Kentarou, Matsukawa Takuo, Harada Kenichi, Fujimoto Naohiro
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2023, Reviewed, No invitation
Lead

The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Furubayashi Nobuki, Minato Akinori, Negishi Takahito, Sakamoto Naotaka, Song Yoohyun, Hori Yoshifumi, Tomoda Toshihisa, Harada Mirii, Tamura Shingo, Kobayashi Hiroki, Wada Yamato, Kuroiwa Kentaro, Seki Narihito, Fujimoto Naohiro, Nakamura Motonobu
OncoTargets and therapy, Nov. 2022, Reviewed, No invitation

Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach.
Harada Kenichi, Shiota Masaki, Minato Akinori, Matsumoto Masahiro, Tomisaki Ikko, Fujisawa Masato, Fujimoto Naohiro
OncoTargets and therapy, May 2021, Reviewed, No invitation

Clinical significance of early kinetics of C‑reactive protein in patients with advanced urothelial carcinoma treated with pembrolizumab: Flare response and baseline levels predict oncological outcomes.
Tomisaki Ikko, Harada Mirii, Sakano Shigeru, Terado Michikazu, Hamasuna Ryoichi, Harada Shuji, Matsumoto Hiroomi, Akasaka Soichiro, Nagata Yujiro, Minato Akinori, Harada Ken-Ichi, Fujimoto Naohiro
Oncology letters, Dec. 2024, Reviewed, No invitation

Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Minato Akinori, Furubayashi Nobuki, Tomoda Toshihisa, Hori Yoshifumi, Kiyoshima Keijiro, Negishi Takahito, Kuroiwa Kentaro, Tomisaki Ikko, Harada Kenichi, Nakamura Motonobu, Fujimoto Naohiro
Translational andrology and urology, Jul. 2024, Reviewed, No invitation
Lead

Reconsideration on Clinical Benefit pf Pelvic Lymph Node Dissection during Radical _x000D_ Prostatectomy for Clinically Localized Prostate Cancer.
Naohiro Fujimoto , Masaki Shiota , Ikko Tomisaki , Akinori Minato , Katsuya Yahara
Urologia Internationalis, Apr. 2019, Reviewed, No invitation

Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki Ikko, Harada Mirii, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Higashijima Katsuyoshi, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Mar. 2022, Null, Null

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy.
Minato Akinori, Noguchi Hirotsugu, Kimuro Rieko, Mirii Harada, Yujiro Nagata, Hasegawa Yoshitaka, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Anticancer research, Jan. 2022, Null, Null

Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
Tsubonuma Yuto, Funakoshi Keita, Takaba Tomohisa, Jyojima Kazumasa, Minato Akinori, Tomisaki Ikko, Harada Kenichi, Fujimoto Naohiro
Journal of UOEH, 2024, Null, Null